Building on these mechanistic insights, our findings demonstrate that BTS functions as a multi-target therapeutic agent that modulates obesity-depression comorbidity by mediating anti-inflammatory pathways, BDNF-NMDAR signaling, and serotonergic pathways in brain. The gene discussed is BDNF; the disease is obesity due to melanocortin 4 receptor deficiency.